Overview
Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women
Status:
Completed
Completed
Trial end date:
2007-02-01
2007-02-01
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
The purpose of this study is to evaluate the efficacy and safety of 100 mg and 150 mg of DVS SR, an extended release form of desvenlafaxine succinate, in comparison to placebo for the treatment of Vasomotor Symptoms (VMS) associated with menopause in a population of postmenopausal women.Phase:
Phase 3Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of PfizerTreatments:
Desvenlafaxine Succinate
Criteria
Inclusion Criteria:- Generally healthy, postmenopausal women who seek treatment for hot flushes
- Body Mass Index (BMI) less than or equal to 40 kg/m2
Other inclusions apply.
Exclusion Criteria:
- Hypersensitivity to Venlafaxine
- Myocardial infarction and/or unstable angina within 6 months of screening
- History of seizure disorder
Other exclusions apply.